| Description |
: It is a potent long acting histamine
H2 Receptor antagonist for the treatment of Duodenal
and gastric ulcer. It inhibits basal and stimulated
secretion of gastric acid, reducing both the volume
and the acid and pepsin content of the secretion.
Ranitidine has a relatively long duration of action
and so a single 150mg dose effectively suppresses
gastric acid secretion for twelve hours.
|
| Composition |
TAB.ORTIDIN-150Each Film-Coated tablet
contains :Ranitidine Hcl. I.P. Equiv to Ranitidine
150 mg.Colour: Sunset Yellow FCF.
TAB.ORTIDIN-300Each Film-Coated tablet contains :Ranitidine
Hcl. I.P. Equiv to Ranitidine 300 mg.Colour: Sunset
Yellow FCF.
|
| Indications |
: Duodenal ulcer; benign gastric ulcer,
reflux oesophagitis; postoperative gastric ulceration
and other hyperacidity syndromes where reduction of
acidity is beneficial.
|
| Dosage |
Duodenal or benign gastric ulcer :
150mg twice daily or 300mg at bed time for 4 to 8
weeks. Zollinger Ellison Syndrome : 600 to 900mg daily
in divided dose.Maintenance dose is 150mg at night
for prevention of ulcer recurrence.
|
| Pack |
: 10 Strips of 10 Tablets each
|
